Physician profile
Matthew P Bashover
NPI 1689761249
$7,130.36
in general payments reported to CMS, 2019-2025
21 companies · $1,520 in 2025
The $1,520 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $800 · 2020: $162 · 2021: $426 · 2022: $1,142 · 2023: $1,673 · 2024: $1,407 · 2025: $1,520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,507 · Entertainment: $92.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,506.55 |
| Entertainment | $92.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,445.50 | 2019-2025 | Acuvue |
| Bausch & Lomb Americas INC. | $1,212.59 | 2022-2025 | Infuse, Miebo, Multi-Focal |
| Sun Pharmaceutical Industries INC. | $610.10 | 2020-2024 | Cequa |
| Oyster Point Pharma, INC. | $573.09 | 2022-2024 | Tyrvaya, Ryzumvi |
| Alcon Vision LLC | $539.00 | 2019-2025 | Precision 1, Dailies Total1, Total30 |
| Lkc Technologies, INC. | $372.34 | 2023-2025 | |
| Aerie Pharmaceuticals, INC. | $288.66 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $283.48 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $237.57 | 2025 | Idosetr |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $226.92 | 2019-2021 | |
| Coopervision INC. | $199.22 | 2019-2024 | Misight Contact Lens, Myday Contact Lens |
| Abb Con-Cise Optical Group LLC | $159.00 | 2025 | Spectacle Lenses, Contact Lens |
| Novartis Pharmaceuticals Corporation | $157.29 | 2019-2023 | |
| Biotissue Holdings INC. | $133.39 | 2024 | |
| Genzyme Corporation | $121.95 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $116.25 | 2023 | Vuity |
| Visioneering Technologies, INC. | $105.21 | 2021 | |
| Optos, INC. | $92.81 | 2023 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Ocular Therapeutix, INC. | $89.49 | 2024 | Dextenza |
| Carl Zeiss Meditec USA, INC. | $88.04 | 2022 | |
| Dompe US, INC. | $78.46 | 2025 | Oxervate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Bashover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.